München (ots) - Der Skywalk auf Langkawi, eine Hängebrücke in schwindelerregender Höhe, gehört zu den ...
EvaluatePharma Japan KK - Now Open for Business in Tokyo
London and Tokyo (ots/PRNewswire) - EvaluatePharma Ltd, the research company, is delighted to announce the official launch of EvaluatePharma Japan KK. With a team based in Tokyo, EvaluatePharma Japan KK will be ideally placed to support our clients and prospects in Japan.
"Japan is a very important market for us. We have managed to build close relationships with our major customers from a distance, but it is now time for us to show our commitment to the Japanese market with a dedicated local operation," said CEO Dr Jonathan de Pass.
With the establishment of EvaluatePharma Japan KK, we welcome Hiroshi Yamazaki, who has joined as a regional director. Mr. Yamazaki is responsible for development of EvaluatePharma's business in Japan. With many years' experience servicing the pharmaceutical industry, he and the EvaluatePharma Japan team are well positioned to expand and support the business in this territory.
The launch was marked with a reception at the British Embassy in Tokyo, where Dr Jonathan de Pass, founder and CEO of EvaluatePharma Ltd, presented "Darwin's Medicine - Survival of the Fittest in the Pharma Industry." Drawing on EvaluatePharma's World Preview 2016 (2011 edition), and "The Future of Pharma" by Professor Brian D. Smith, Dr de Pass discussed the evolutionary forces shaping the pharmaceuticals industry in the face of catastrophic loss of revenue post "patent cliff" and the alarming decline in R&D productivity.
Notes to editors
About EvaluatePharma (R) - http://www.evaluatepharma.com
Set up in 1996 by former top pharma analyst Dr. Jonathan de Pass, EvaluatePharma(R) is the premier source for pharma and biotech analysis.
EvaluatePharma was the first company to supply reliable consensus forecasts of global drug sales and now provides standardised worldwide financial and forecast models with consensus product forecasts to 2016, data on R&D pipelines, licensing deals, patent risk and M&A deals, along with analytical tools that include Merge Company and Peer Group Analyzer and NPV (Net Present Value) analysis for more than 3000 products.
Launched in 2007, EvaluatePharma(R)Alpha offers an off-the-shelf valuation service to quantify the impact of market events on product, portfolio and company valuation - NPV Analyzer, Calendar of Events and the daily news service EP Vantage.
For media enquiries please contact:
Mr Hiroshi Yamazaki
Business Development Director Japan, EvaluatePharma Japan KK